<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331042</url>
  </required_header>
  <id_info>
    <org_study_id>SM-A-05</org_study_id>
    <nct_id>NCT03331042</nct_id>
  </id_info>
  <brief_title>SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.</brief_title>
  <official_title>A Randomized, Double-Blind, Single-Dose, 4-Way Crossover Study to Assess the Efficacy and Safety of SM-1 (50-mg Diphenhydramine, 5-mg Delayed-Release Zolpidem, and 0.5-mg Delayed-Release Lorazepam) Versus 2 Comparators (50-mg Diphenhydramine and 5-mg Delayed-Release Zolpidem; 50-mg Diphenhydramine and 0.5-mg Delayed-Release Lorazepam) and Placebo in a 5-Hour Phase Advance Model of Transient Insomnia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequential Medicine Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequential Medicine Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness, safety and tolerability of a
      combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult
      participants who sometimes have difficulty in falling asleep or staying asleep, but who do
      not have chronic insomnia. Participants will receive SM-1, or a combination of
      diphenhydramine and zolpidem, or a combination of diphenhydramine and lorazepam, or placebo
      during 4 one-night stays at a sleep center.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time (TST)</measure>
    <time_frame>8 hours</time_frame>
    <description>TST efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-defined total sleep time (TST)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency to Persistent Sleep (LPS)</measure>
    <time_frame>8 hours</time_frame>
    <description>Efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep induction, the amount of time it takes the subject to fall asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Awakenings (NAW)</measure>
    <time_frame>8 hours</time_frame>
    <description>NAW efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wakefulness After Sleep Onset (WASO)</measure>
    <time_frame>8 hours</time_frame>
    <description>WASO efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance as the amount of time spent awake after falling asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleepiness Scale (KSS) of Morning Alertness.</measure>
    <time_frame>Up to Visit 5</time_frame>
    <description>Morning alertness measured by Karolinska Sleepiness Scale (KSS). KSS ranges from 1-9, with higher numbers indicating sleepier and lower numbers more alert.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Correct on Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Up to Visit 5</time_frame>
    <description>Morning alertness measured by DSST. The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Total Sleep Time (sTST)</measure>
    <time_frame>Up to 22 days.</time_frame>
    <description>Subject reported TST from Post-Sleep Questionnaire (PSQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleep Onset Latency (sSOL)</measure>
    <time_frame>Up to 22 days.</time_frame>
    <description>Subject reported SOL, the amount of time the subject felt it took to fall asleep, from Post-Sleep Questionnaire (PSQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Number of Awakenings (sNAW)</measure>
    <time_frame>Up to 22 days.</time_frame>
    <description>Subject reported NAW from Post-Sleep Questionnaire (PSQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants According to Sleep Quality</measure>
    <time_frame>Up to 22 days.</time_frame>
    <description>Subject reported sleep quality, how well the subject felt he or she slept, from Post-Sleep Questionnaire (PSQ).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Minutes of Sleep in Stages N1, N2, N3, Rapid Eye Movement (REM) and Latency to REM Onset.</measure>
    <time_frame>8 hours</time_frame>
    <description>Effect of SM-1 and the two 2-drug combination products (diphenhydramine plus zolpidem and diphenhydramine plus lorazepam) on sleep stage distribution.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-1</intervention_name>
    <description>3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D+Z</intervention_name>
    <description>2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D+L</intervention_name>
    <description>2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written consent form.

          -  Experienced at least 1 prior episode of transient insomnia meeting all of the
             following criteria: difficulty falling asleep or staying asleep; next day impairment
             or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week;
             duration of less than 1 month or more than 1 month of intermittent episodes.

          -  Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than
             2 hours over a week. Potential participants will be required to complete a paper diary
             for a minimum of 7 days during the screening period, with at least 5 entries completed
             over the 7 days.

          -  Body Mass Index (BMI) between 19 and 32 kg/m2.

          -  Good general health, as determined by a thorough medical, sleep and psychiatric
             history review, brief physical examination including vital sign measurements, and an
             assessment of screening laboratory test results.

          -  Female subjects of childbearing potential must be using an acceptable method of
             contraception during the study and for the 30 days following the last dose of study
             drug, and must have a negative urine pregnancy test at every study visit. Female
             subjects of non-childbearing potential are not required to use contraception if they
             have been surgically sterilized or are post-menopausal as defined by the cessation of
             menses for a period of at least 2 years before screening.

          -  Male subjects must use an acceptable method of contraception during the study and for
             the 30 days following the last dose of study drug.

          -  Willing and able to be confined to the study center for 1 night in each of 4 treatment
             periods, as required by the protocol.

          -  Refrains from the use of alcohol within 24 hours of check-in for each of 4 treatment
             periods involving an overnight stay at the study center.

          -  Refrains from napping (any sleep episode occurring outside subject's main sleep
             episode) on days of check-in for each of 4 treatment periods involving an overnight
             stay at the study center.

        Exclusion Criteria:

          -  Females who are pregnant, breast-feeding, or planning a pregnancy during the study
             period.

          -  Clinically significant medical disorder or currently unstable medical condition that,
             in the opinion of the investigator, would confound the results of the study.

          -  Abnormal laboratory value at screening, judged clinically significant by the
             investigator.

          -  History or current evidence of severe hepatic (liver) impairment.

          -  Clinically significant psychiatric illness, or the history or presence of a major
             psychiatric illness in the past year.

          -  Clinically significant abnormal finding on physical examination, as determined by the
             investigator.

          -  Lifetime history of seizure disorder (other than childhood febrile seizures) or
             serious head injury.

          -  History of chronic insomnia or other sleep disorders, such as sleep apnea, narcolepsy,
             parasomnia, restless leg syndrome, or circadian rhythm disorder.

          -  Air travel across more than 2 time zones, an expected change in sleep schedule, or
             involvement in night work or shift work within 1 month before screening or during the
             study period.

          -  Reports a recent history of napping of more than once per week.

          -  History of alcohol or substance use disorder within the year before screening, or
             current evidence of alcohol or substance use disorder.

          -  Self-report of a usual consumption of more than 14 units of alcohol per week. One unit
             of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of liquor.

          -  Regular consumption of more than 500 mg of caffeine per day.

          -  History of routinely smoking during sleep period.

          -  Discontinuation of smoking or participation in a smoking cessation program within 30
             days of screening or plans to discontinue smoking during the study.

          -  Positive urine drug screen at screening.

          -  Positive alcohol breathalyzer test at any visit.

          -  History of allergy or known sensitivity, hypersensitivity, or adverse reaction to
             diphenhydramine, zolpidem, or lorazepam or other drugs of the same pharmaceutical
             classes.

          -  Use of any medication which affects sleep-wake function within 5 half-lives or 2
             weeks, whichever is longer, before screening until study completion. This includes
             prescription, over-the-counter (OTC), and herbal (e.g. valerian root, melatonin)
             medications.

          -  Use of any investigational drug within 30 days or 5 half-lives, whichever is longer,
             before screening.

          -  Planned surgery (inpatient or outpatient) during the study period.

          -  Employee or family member of the investigator or study center personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>May 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2019</results_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Transient Insomnia</keyword>
  <keyword>Sleep initiation and maintenance disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03331042/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03331042/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects were randomized to one of four possible planned order of treatments (Sequences) given in the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1</title>
          <description>SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2</title>
          <description>D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3</title>
          <description>D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4</title>
          <description>Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
SM-1: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
D+Z: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
D+L: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Placebo: Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="13.68"/>
                    <measurement group_id="B2" value="39.3" spread="13.29"/>
                    <measurement group_id="B3" value="36.1" spread="11.68"/>
                    <measurement group_id="B4" value="41.6" spread="11.77"/>
                    <measurement group_id="B5" value="38.9" spread="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Sleep Time (TST)</title>
        <description>TST efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-defined total sleep time (TST)</description>
        <time_frame>8 hours</time_frame>
        <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Subjects received a single dose of the triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine Plus Zolpidem</title>
            <description>Subjects received a single dose of the 2-drug product containing Diphenhydramine plus Zolpidem; i.e., SM-1 without Lorazepam</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine Plus Lorazepam</title>
            <description>Subjects received a single dose of the 2-drug product containing Diphenhydramine plus Lorazepam; i.e., SM-1 without Zolpidem</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a single dose of a Placebo matching the appearance of the active treatments but containing no active drug components</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time (TST)</title>
          <description>TST efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-defined total sleep time (TST)</description>
          <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.82" spread="68.074"/>
                    <measurement group_id="O2" value="404.83" spread="47.252"/>
                    <measurement group_id="O3" value="397.28" spread="56.982"/>
                    <measurement group_id="O4" value="307.38" spread="107.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Latency to Persistent Sleep (LPS)</title>
        <description>Efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep induction, the amount of time it takes the subject to fall asleep.</description>
        <time_frame>8 hours</time_frame>
        <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Latency to Persistent Sleep (LPS)</title>
          <description>Efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep induction, the amount of time it takes the subject to fall asleep.</description>
          <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.59" spread="18.548"/>
                    <measurement group_id="O2" value="23.10" spread="29.145"/>
                    <measurement group_id="O3" value="23.55" spread="29.125"/>
                    <measurement group_id="O4" value="39.25" spread="73.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Awakenings (NAW)</title>
        <description>NAW efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance.</description>
        <time_frame>8 hours</time_frame>
        <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Awakenings (NAW)</title>
          <description>NAW efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance.</description>
          <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="6.06"/>
                    <measurement group_id="O2" value="10.7" spread="6.22"/>
                    <measurement group_id="O3" value="11.0" spread="5.91"/>
                    <measurement group_id="O4" value="8.6" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wakefulness After Sleep Onset (WASO)</title>
        <description>WASO efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance as the amount of time spent awake after falling asleep.</description>
        <time_frame>8 hours</time_frame>
        <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Wakefulness After Sleep Onset (WASO)</title>
          <description>WASO efficacy of SM-1 versus placebo, combination product diphenhydramine plus zolpidem and combination product diphenhydramine plus lorazepam measured by polysomnography (PSG)-measured sleep maintenance as the amount of time spent awake after falling asleep.</description>
          <population>Full analysis set consisted of all subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.11" spread="66.673"/>
                    <measurement group_id="O2" value="58.83" spread="41.834"/>
                    <measurement group_id="O3" value="63.91" spread="49.841"/>
                    <measurement group_id="O4" value="140.06" spread="99.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Karolinska Sleepiness Scale (KSS) of Morning Alertness.</title>
        <description>Morning alertness measured by Karolinska Sleepiness Scale (KSS). KSS ranges from 1-9, with higher numbers indicating sleepier and lower numbers more alert.</description>
        <time_frame>Up to Visit 5</time_frame>
        <population>The Safety Population included all subjects that received any study drug, and were grouped by actual treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Karolinska Sleepiness Scale (KSS) of Morning Alertness.</title>
          <description>Morning alertness measured by Karolinska Sleepiness Scale (KSS). KSS ranges from 1-9, with higher numbers indicating sleepier and lower numbers more alert.</description>
          <population>The Safety Population included all subjects that received any study drug, and were grouped by actual treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.99"/>
                    <measurement group_id="O2" value="3.9" spread="2.01"/>
                    <measurement group_id="O3" value="3.9" spread="2.02"/>
                    <measurement group_id="O4" value="3.9" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Correct on Digit Symbol Substitution Test (DSST)</title>
        <description>Morning alertness measured by DSST. The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93</description>
        <time_frame>Up to Visit 5</time_frame>
        <population>Safety Population included all subjects that received any study drug, and were grouped by actual treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number Correct on Digit Symbol Substitution Test (DSST)</title>
          <description>Morning alertness measured by DSST. The digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment. Scores on the DSST range from 0-93</description>
          <population>Safety Population included all subjects that received any study drug, and were grouped by actual treatment.</population>
          <units>number correct</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" spread="14.21"/>
                    <measurement group_id="O2" value="57.6" spread="14.98"/>
                    <measurement group_id="O3" value="58.3" spread="16.20"/>
                    <measurement group_id="O4" value="60.4" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Total Sleep Time (sTST)</title>
        <description>Subject reported TST from Post-Sleep Questionnaire (PSQ).</description>
        <time_frame>Up to 22 days.</time_frame>
        <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Total Sleep Time (sTST)</title>
          <description>Subject reported TST from Post-Sleep Questionnaire (PSQ).</description>
          <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.1" spread="55.97"/>
                    <measurement group_id="O2" value="419.0" spread="79.60"/>
                    <measurement group_id="O3" value="422.9" spread="83.63"/>
                    <measurement group_id="O4" value="368.7" spread="107.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Sleep Onset Latency (sSOL)</title>
        <description>Subject reported SOL, the amount of time the subject felt it took to fall asleep, from Post-Sleep Questionnaire (PSQ).</description>
        <time_frame>Up to 22 days.</time_frame>
        <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Sleep Onset Latency (sSOL)</title>
          <description>Subject reported SOL, the amount of time the subject felt it took to fall asleep, from Post-Sleep Questionnaire (PSQ).</description>
          <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="24.30"/>
                    <measurement group_id="O2" value="27.7" spread="34.29"/>
                    <measurement group_id="O3" value="26.6" spread="51.81"/>
                    <measurement group_id="O4" value="34.8" spread="55.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Number of Awakenings (sNAW)</title>
        <description>Subject reported NAW from Post-Sleep Questionnaire (PSQ).</description>
        <time_frame>Up to 22 days.</time_frame>
        <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine Plus Zolpidem</title>
            <description>Diphenhydramine plus Zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine Plus Lorazepam</title>
            <description>Diphenhydramine plus Lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Number of Awakenings (sNAW)</title>
          <description>Subject reported NAW from Post-Sleep Questionnaire (PSQ).</description>
          <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.73"/>
                    <measurement group_id="O2" value="2.2" spread="2.19"/>
                    <measurement group_id="O3" value="2.2" spread="1.47"/>
                    <measurement group_id="O4" value="2.8" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants According to Sleep Quality</title>
        <description>Subject reported sleep quality, how well the subject felt he or she slept, from Post-Sleep Questionnaire (PSQ).</description>
        <time_frame>Up to 22 days.</time_frame>
        <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-1</title>
            <description>Triple drug combination</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine and Zolpidem</title>
            <description>Diphenhydramine and zolpidem</description>
          </group>
          <group group_id="O3">
            <title>Diphenhydramine and Lorazepam</title>
            <description>diphenhydramine and lorazepam</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants According to Sleep Quality</title>
          <description>Subject reported sleep quality, how well the subject felt he or she slept, from Post-Sleep Questionnaire (PSQ).</description>
          <population>All subjects who were randomized to a treatment sequence, and had taken any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 = poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 = fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 = good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 = excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Minutes of Sleep in Stages N1, N2, N3, Rapid Eye Movement (REM) and Latency to REM Onset.</title>
        <description>Effect of SM-1 and the two 2-drug combination products (diphenhydramine plus zolpidem and diphenhydramine plus lorazepam) on sleep stage distribution.</description>
        <time_frame>8 hours</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 until 7 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SM-1</title>
          <description>Triple drug combination</description>
        </group>
        <group group_id="E2">
          <title>Diphenhydramine Plus Zolpidem</title>
          <description>Diphenhydramine plus Zolpidem</description>
        </group>
        <group group_id="E3">
          <title>Diphenhydramine Plus Lorazepam</title>
          <description>Diphenhydramine plus Lorazepam</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>nightmare</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="abdominal pain">abdominal pain</sub_title>
                <description>upper abdominal pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="asthenia">asthenia</sub_title>
                <description>asthenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="fatigue">fatigue</sub_title>
                <description>fatigue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nightmare</sub_title>
                <description>Nightmare</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title vocab="somnolence">somnolence</sub_title>
                <description>somnolence</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Dahl</name_or_title>
      <organization>Sequential Medicine Ltd</organization>
      <phone>617-818-2735</phone>
      <email>tadahl@outlook.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

